Your browser is no longer supported. Please, upgrade your browser.
Settings
GTXI GTx, Inc. daily Stock Chart
GTXI [NASD]
GTx, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own13.50% Shs Outstand15.34M Perf Week-26.58%
Market Cap51.70M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.82M Perf Month-23.41%
Income-17.70M PEG- EPS next Q- Inst Own9.30% Short Float2.07% Perf Quarter-30.94%
Sales- P/S- EPS this Y8.60% Inst Trans-8.64% Short Ratio4.48 Perf Half Y-58.93%
Book/sh0.89 P/B3.79 EPS next Y- ROA- Target Price7.00 Perf Year-55.07%
Cash/sh1.08 P/C3.13 EPS next 5Y0.00% ROE- 52W Range3.28 - 11.19 Perf YTD-36.17%
Dividend- P/FCF- EPS past 5Y27.40% ROI- 52W High-69.89% Beta1.84
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low2.74% ATR0.35
Employees26 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)28.16 Volatility12.94% 8.96%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.80 Prev Close3.37
ShortableYes LT Debt/Eq0.00 EarningsJun 14 BMO Payout- Avg Volume22.29K Price3.37
Recom3.00 SMA20-25.21% SMA50-26.91% SMA200-44.80% Volume17,752 Change0.00%
Dec-09-16Reiterated Jefferies Hold $10 → $7
Apr-05-13Initiated Stifel Buy $7
Oct-14-11Initiated Rodman & Renshaw Mkt Outperform $7
Jul-20-11Initiated Wedbush Outperform $13
Oct-27-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
May-26-10Reiterated Rodman & Renshaw Mkt Underperform $1.75 → $1.25
Mar-17-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1.75
Jan-26-09Reiterated Leerink Swann Mkt Perform $18 → $10
Jan-22-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
May-23-08Downgrade Cowen & Co Outperform → Neutral
Mar-25-08Initiated Rodman & Renshaw Mkt Outperform $22
Nov-07-07Reiterated Lazard Capital Buy $28 → $31
Nov-06-07Reiterated Broadpoint Capital Buy $26 → $29
Oct-11-07Initiated Wachovia Outperform
Sep-13-07Initiated First Albany Buy $26
May-10-07Initiated Citigroup Hold $24
Apr-30-07Downgrade Leerink Swann Outperform → Mkt Perform
Apr-24-07Reiterated HSBC Securities Overweight $25 → $29
Apr-18-07Reiterated Lazard Capital Buy $25 → $28
Apr-18-07Reiterated AG Edwards Buy $23 → $28
May-15-17 07:10AM  GTx reports 1Q loss Associated Press
07:00AM  GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results Business Wire
May-11-17 07:00AM  GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting Business Wire -5.66%
May-03-17 07:00AM  GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics Business Wire
Mar-30-17 01:04PM  GTX INC /DE/ Financials
Mar-15-17 07:40AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:12AM  GTx reports 4Q loss Associated Press
07:07AM  Q4 2016 GTX Inc Earnings Release - Before Market Open
07:00AM  GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results Business Wire
Mar-07-17 07:00AM  GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 Business Wire -8.22%
Jan-09-17 04:31PM  GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers -5.05%
Dec-21-16 12:16PM  GTX INC /DE/ Files SEC form 8-K, Other Events -12.48%
Dec-16-16 05:24AM  Is GTx, Inc. (GTXI) A Good Stock To Buy? Insider Monkey
05:24AM  Is GTx, Inc. (GTXI) A Good Stock To Buy? at Insider Monkey
Dec-08-16 03:13PM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.18%
07:00AM  GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer Business Wire
Dec-06-16 10:20AM  GTx Declares 1-For-10 Reverse Stock Split (GTXI) Investopedia
10:20AM  GTx Declares 1-For-10 Reverse Stock Split (GTXI) at Investopedia
Dec-05-16 04:07PM  GTX INC /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statement -14.10%
08:34AM  GTx, Inc. Announces 1-for-10 Reverse Stock Split Business Wire
Dec-01-16 08:38AM  GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
08:38AM  GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-28-16 10:25AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.08%
07:00AM  Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer Business Wire
Nov-23-16 07:00AM  GTx Announces Webcast of Corporate Presentation at the 28th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-17-16 02:31PM  Heres What To Look For When The Real GTx, Inc. (GTXI) Data Hits at Insider Monkey
08:15AM  Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone Accesswire
Nov-16-16 07:31AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.32%
07:00AM  GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer Business Wire
Nov-11-16 07:00AM  GTx Announces Webcast of Corporate Presentation at the Stifel 2016 Healthcare Conference Business Wire
Nov-07-16 05:24PM  GTX INC /DE/ Files SEC form 10-Q, Quarterly Report
Nov-03-16 07:35AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -7.89%
07:06AM  GTx reports 3Q loss
07:00AM  GTx Provides Corporate Update and Reports Third Quarter 2016 Financial Results Business Wire
Oct-18-16 05:27PM  Insider Invests in GTx
Oct-12-16 07:10AM  GTX INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Cond
07:00AM  GTx Announces $14.0 Million Registered Direct Common Stock Offering Business Wire
Sep-08-16 11:26AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits +23.81%
07:00AM  GTx Achieves Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer Business Wire
Sep-02-16 07:00AM  GTx Announces Webcast of Corporate Presentation at Bairds 2016 Healthcare Conference Business Wire
Sep-01-16 07:32AM  GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
07:00AM  GTx Appoints Dr. Garry Neil to Board of Directors Business Wire
Aug-11-16 03:19PM  Nvidia: 'GTX1080 Will Power Them to Blow Away Q2 Estimate, Says M Science at Barrons.com
Aug-09-16 07:31AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:09AM  GTx reports 2Q loss
07:00AM  GTx Provides Corporate Update and Reports Second Quarter 2016 Financial Results Business Wire
Jun-22-16 10:01AM  GTX INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran
Jun-21-16 08:15AM  GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session -9.53%
Jun-08-16 06:07PM  GTx, Inc. :GTXI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
Jun-02-16 07:00AM  GTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference Business Wire -8.45%
May-16-16 07:00AM  GTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2016 Business Wire
May-10-16 07:32AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:14AM  GTx posts 1Q profit
07:07AM  Q1 2016 GTX Inc Earnings Release - Before Market Open
07:00AM  GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results Business Wire
May-09-16 05:16PM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  GTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting Business Wire
Apr-27-16 07:00AM  GTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016 Business Wire -6.43%
Apr-06-16 05:24PM  Edited Transcript of GTXI earnings conference call or presentation 3-Mar-16 2:00pm GMT
Mar-15-16 04:18PM  GTX INC /DE/ Files SEC form 10-K, Annual Report
Mar-03-16 09:00AM  GTX Inc Earnings Call scheduled for 9:00 am ET today -10.14%
07:31AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:17AM  GTx reports 4Q loss
07:07AM  Q4 2015 GTX Inc Earnings Release - Before Market Open
07:00AM  GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results Business Wire
Feb-24-16 07:00AM  GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx SARMs on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting Business Wire +6.83%
Feb-19-16 04:32PM  GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
Feb-18-16 07:00AM  GTx, Inc. to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast Business Wire
Jan-13-16 09:56AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.41%
07:00AM  GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence Business Wire
Dec-23-15 05:01PM  GTX INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran
Dec-16-15 08:20AM  Strength Seen in GTX (GTXI): Stock Adds 7.8% in Session -6.02%
Dec-01-15 09:05AM  Equities on the Move - Research on GTX Inc, Juniper Pharmaceuticals, Catabasis Pharmaceuticals and Amber Road Accesswire +5.38%
Nov-29-15 04:02AM  Is Jernigan Capital Inc (JCAP) a Good Stock To Buy? at Insider Monkey
Nov-26-15 07:40AM  Radio One, Inc. (ROIAK): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-23-15 05:21PM  GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
Nov-09-15 04:59PM  GTX INC /DE/ Files SEC form 10-Q, Quarterly Report
Nov-02-15 03:55PM  Edited Transcript of GTXI earnings conference call or presentation 29-Oct-15 1:00pm GMT
Oct-29-15 09:39AM  GTx posts 3Q profit
09:00AM  GTX Inc Earnings Call scheduled for 9:00 am ET today
07:31AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q3 2015 GTX Inc Earnings Release - Time Not Supplied
07:00AM  GTx Provides Corporate Update and Reports Third Quarter 2015 Financial Results Business Wire
Oct-15-15 07:00AM  GTx, Inc. To Host Third Quarter 2015 Financial Results Conference Call and Webcast Business Wire
Oct-13-15 07:31AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence Business Wire
Oct-07-15 08:15AM  GTX (GTXI) Shows Strength: Stock Adds 37.8% in Session -14.16%
Oct-06-15 07:32AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits +37.79%
07:00AM  GTx Announces Enrollment of First Patient in Phase 2 Clinical Trial of Enobosarm in Triple Negative Breast Cancer Business Wire
Sep-29-15 07:31AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  GTx Announces Enrollment of First Patient in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer Business Wire
Sep-21-15 10:39AM  GTx, Inc. breached its 50 day moving average in a Bullish Manner : September 21, 2015 -9.17%
Aug-21-15 09:42AM  Edited Transcript of GTXI earnings conference call or presentation 6-Aug-15 1:00pm GMT -8.79%
Aug-16-15 08:12PM  10-Q for GTx, Inc. at Company Spotlight
Aug-10-15 06:18PM  GTX INC /DE/ Files SEC form 10-Q, Quarterly Report +9.79%
Aug-06-15 03:39PM  GTx earnings released, explores SARM potential at bizjournals.com
09:00AM  GTX Inc Earnings Call scheduled for 9:00 am ET today
08:21AM  GTx reports 2Q loss
07:31AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q2 2015 GTX Inc Earnings Release - Time Not Supplied
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pyramid Peak Foundation10% OwnerOct 14Buy0.817,716,0496,250,00038,249,528Oct 17 05:10 PM
Wills Robert JamesExecutive ChairmanJun 16Buy0.65100,00065,3601,200,000Jun 20 10:19 AM